Comparison of Efficacy and Safety of First-Line Chemoimmunotherapy in Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Network Meta-Analysis
Open Access
- 6 February 2023
- journal article
- review article
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2023, 1-12
Abstract
Background. Chemoimmunotherapy has become the first-line treatment for advanced esophageal squamous cell carcinoma (ESCC). We aimed to compare the efficacy and toxicity of different chemoimmunotherapy combinations to determine the optimal treatment option. Methods. PubMed, Web of Science, Cochrane Library, Embase, and abstracts of recent relevant meetings were searched to identify phase III randomized controlled trials (RCTs) of first-line programmed cell death-1 (PD-1)/its receptor (PD-L1) inhibitors plus chemotherapy for ESCC up to July 2022. A network meta-analysis (NMA) following Bayesian approaches was conducted in R software. Result. Our study included six RCTs and 3,611 patients. According to the NMA, toripalimab plus chemotherapy ranked first to prolong overall survival (OS). Sintilimab plus chemotherapy and camrelizumab plus chemotherapy consistently yielded the greatest benefits regarding progression-free survival (PFS). The maximal complete response rate (CRR) and objective response rate (ORR) were achieved with nivolumab plus chemotherapy. Tislelizumab plus chemotherapy attained the highest likelihood of achieving a disease control rate (DCR). The addition of immunotherapy to chemotherapy was associated with improved survival and increased adverse events. Subgroup analysis revealed that patients with PD-L1 tumor positive score (TPS) 10 showed a better OS than those with lower values when undergoing first-line chemoimmunotherapy. Anti-PD-1 inhibitor with platinumpluspaclitaxel (TP) regimen showed a superior PFS benefit over anti-PD-1 inhibitor with platinumplusfluorouracil (FP) regimen. Conclusion. The NMA analysis suggested that sintilimab plus chemotherapy was the preferred regimen for treatment-naive advanced ESCC patients with the best balance between efficacy and safety. Anti-PD-1 inhibitors with the TP regimen were associated with more favorable PFS than those with the FP regimen.Keywords
This publication has 43 references indexed in Scilit:
- Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysisThe Lancet Psychiatry, 2018
- Cancer immunotherapy using checkpoint blockadeScience, 2018
- Oesophageal cancerThe Lancet, 2017
- Integrated genomic characterization of oesophageal carcinomaNature, 2017
- Trends in esophageal cancer survival in United States adults from 1973 to 2009: A SEER database analysisJournal of Gastroenterology and Hepatology, 2016
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 TherapyClinical Cancer Research, 2014
- Conceptual and Technical Challenges in Network Meta-analysisAnnals of Internal Medicine, 2013
- Interpreting Trial Results in Light of Conflicting Evidence: A Bayesian Analysis of Adjuvant Chemotherapy for Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- Are Squamous and Adenocarcinomas of the Esophagus the Same Disease?Seminars in Radiation Oncology, 2007
- Measuring inconsistency in meta-analysesBMJ, 2003